Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland – the SAKK 95/16 prostate study. Swiss Med Wkly [Internet]. 2021 Mar. 1 [cited 2025 Oct. 14];151(0910):w20464. Available from: https://smw.ch/index.php/smw/article/view/2968